Abstract Objectives To develop the European League Against Rheumatism (EULAR)
recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis …

ANCA-associated vasculitides (AAV) are a group of rare, primary, systemic necrotizing small-
vessel vasculitides. Granulomatosis with polyangiitis and microscopic polyangiitis account …

Background More effective and safer treatments are needed for antineutrophil cytoplasmic
antibody (ANCA)–associated vasculitis. Methods We conducted a randomized trial with a 2 …

Objective Following induction of remission with rituximab in anti-neutrophil cytoplasmic
antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with …

B cells are important in the pathogenesis of many, and perhaps all, immune-mediated
diseases. Each B cell expresses a single B cell receptor (BCR), and the diverse range of …

The clinical course of autoimmune and infectious disease varies greatly, even between
individuals with the same condition. An understanding of the molecular basis for this …

Objectives To evaluate the efficacy of rituximab (RTX) in IgG4-related disease (IgG4-RD) in
an open-label pilot trial. Methods We treated 30 IgG4-RD patients with two doses of RTX …

Objectives To develop an Outcome Measures in Rheumatology (OMERACT)
ultrasonography score for monitoring disease activity in giant cell arteritis (GCA) and …

Background The 18-month efficacy of a single course of rituximab as compared with
conventional immunosuppression with cyclophosphamide followed by azathioprine in …

Background Cyclophosphamide and glucocorticoids have been the cornerstone of
remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA) …